AbbVie Inc (ABBV)

62.09
0.15 0.24
NYSE : Health Care
Prev Close 61.94
Open 61.90
Day Low/High 61.49 / 62.23
52 Wk Low/High 54.24 / 68.12
Volume 6.52M
Avg Volume 7.34M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 97.80B
EPS 3.70
P/E Ratio 12.73
Div & Yield 2.56 (4.20%)

Latest News

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Eli Lilly Is Great Stock to Buy Now

Eli Lilly Is Great Stock to Buy Now

Here's why the pharmaceutical company is a solid addition to your portfolio.

AbbVie Becomes #173 Most Shorted S&P 500 Component, Replacing Newell Brands

AbbVie Becomes #173 Most Shorted S&P 500 Component, Replacing Newell Brands

The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Portfolio Update: AbbVie, Pfizer and Sonoco Report Earnings; and Don't Miss These Must-Own Dates!

An update of earnings, payout dates and upcoming dividend reminders.

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

U.S. FDA Grants Priority Review To AbbVie For Its Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes

Trump Investing: Listen, Don't Overreact

Trump Investing: Listen, Don't Overreact

Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.

You Can Also Get High on Marijuana Stocks -- Here's How

You Can Also Get High on Marijuana Stocks -- Here's How

Everyone else is doing it.

Abbvie Shares Fall on Mixed Earnings Report

Abbvie Shares Fall on Mixed Earnings Report

The biotech saw shares fall 2.3% after reporting in-line earnings and worse-than-expected revenue.

Create a 'Barbell' of Value, Income Stocks

Create a 'Barbell' of Value, Income Stocks

Value stocks will extend their outperformance over growth stocks that began last year.

Market Recon: Danger Is Coming to a Market Near You

Market Recon: Danger Is Coming to a Market Near You

What do you do when the music stops? Are you the kid without a chair?

DSA Earnings Potpourri

Reviewing 6 recent portfolio-name earnings reports and previewing 3 on tap.

What to Watch Friday: American Airlines Earnings, Fourth-Quarter GDP

What to Watch Friday: American Airlines Earnings, Fourth-Quarter GDP

On Friday, investors will get quarterly results from American Airlines and the release of fourth quarter gross domestic product.

AbbVie Initiates Phase 2 Clinical Trial Programs For ABBV-8E12, An Investigational Anti-Tau Antibody, In Early Alzheimer's Disease And Progressive Supranuclear Palsy

AbbVie Initiates Phase 2 Clinical Trial Programs For ABBV-8E12, An Investigational Anti-Tau Antibody, In Early Alzheimer's Disease And Progressive Supranuclear Palsy

- Initiation of Phase 2 clinical trial programs in early Alzheimer's disease and progressive supranuclear palsy (PSP) is part of ongoing commitment to investigate ABBV-8E12 and tau-focused approaches to delay disease progression

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application For AbbVie's Investigational Regimen Of Glecaprevir/Pibrentasvir (G/P) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The Stock Market Is Shaky and Overbought, and Now There Is Trump

The weak companies could be clobbered.

U.S. FDA Approves IMBRUVICA® (ibrutinib) As First Treatment Specifically Indicated For Relapsed/Refractory Marginal Zone Lymphoma (MZL) - A Rare Type Of Non-Hodgkin's Lymphoma

U.S. FDA Approves IMBRUVICA® (ibrutinib) As First Treatment Specifically Indicated For Relapsed/Refractory Marginal Zone Lymphoma (MZL) - A Rare Type Of Non-Hodgkin's Lymphoma

- This marks the seventh FDA approval and fifth disease indication for IMBRUVICA since the medication's initial approval in 2013

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

An All-Inclusive Portfolio Update

Earnings previews, company updates, dividend reminders -- the works.

Biotech Just Got Trumped

Biotech Just Got Trumped

But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.

Don't Forget Today's AbbVie Must-Own Date

The stock has gained 15% over the past year and we maintain the company is attractive to purchase for the secure payout.